DexCom, Inc. $DXCM Holdings Decreased by Greenleaf Trust

Key Points

• Greenleaf Trust reduced its holdings in DexCom, Inc. by 24.8% during the second quarter, now owning 12,944 shares valued at approximately $1.13 million.
• DexCom's stock recently traded at $66.08, with a market capitalization of $25.91 billion and a debt-to-equity ratio of 0.48.
• Company earnings beat analyst expectations, reporting $1.16 billion in revenue and $0.48 EPS for the last quarter, reflecting a 15.2% increase year-over-year.

Greenleaf Trust decreased its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 24.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,944 shares of the medical device company's stock after selling 4,265 shares during the quarter. Greenleaf Trust's holdings in DexCom were worth $1,130,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Golden State Wealth Management LLC grew its stake in DexCom by 211.2% during the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock valued at $27,000 after acquiring an additional 264 shares in the last quarter. Zions Bancorporation National Association UT purchased a new position in DexCom during the first quarter valued at approximately $27,000. Anderson Financial Strategies LLC purchased a new position in DexCom during the first quarter valued at approximately $37,000. Alpine Bank Wealth Management purchased a new position in DexCom during the first quarter valued at approximately $40,000. Finally, Private Trust Co. NA grew its holdings in shares of DexCom by 99.4% during the 1st quarter. Private Trust Co. NA now owns 672 shares of the medical device company's stock valued at $46,000 after acquiring an additional 335 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company's stock.

DexCom Stock Down 1.8%

DXCM stock opened at $66.08 on Thursday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35. DexCom, Inc. has a 52-week low of $57.52 and a 52-week high of $93.25. The company has a 50-day moving average of $77.16 and a two-hundred day moving average of $77.94. The stock has a market capitalization of $25.91 billion, a price-to-earnings ratio of 45.89, a price-to-earnings-growth ratio of 1.41 and a beta of 1.47.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The company had revenue of $1.16 billion during the quarter, compared to analysts' expectations of $1.13 billion. During the same period in the prior year, the company earned $0.43 earnings per share. The business's quarterly revenue was up 15.2% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

Insiders Place Their Bets

In other news, Director Kyle Malady sold 667 shares of the stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $80.86, for a total value of $53,933.62. Following the completion of the sale, the director directly owned 22,667 shares of the company's stock, valued at approximately $1,832,853.62. This represents a 2.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Michael Jon Brown sold 500 shares of the stock in a transaction on Friday, August 15th. The shares were sold at an average price of $80.29, for a total transaction of $40,145.00. Following the completion of the sale, the executive vice president directly owned 94,102 shares of the company's stock, valued at approximately $7,555,449.58. This trade represents a 0.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 6,849 shares of company stock valued at $564,733 over the last ninety days. 0.32% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Truist Financial assumed coverage on shares of DexCom in a report on Monday, June 16th. They set a "buy" rating and a $102.00 price target on the stock. Oppenheimer downgraded DexCom from an "outperform" rating to a "market perform" rating in a research note on Monday, September 8th. Canaccord Genuity Group restated a "buy" rating and issued a $106.00 target price on shares of DexCom in a research note on Monday. Wall Street Zen cut DexCom from a "strong-buy" rating to a "buy" rating in a research note on Sunday, August 10th. Finally, Robert W. Baird lowered their price target on DexCom from $112.00 to $90.00 and set an "outperform" rating for the company in a research note on Friday, September 26th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, DexCom presently has a consensus rating of "Moderate Buy" and a consensus price target of $98.32.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.